Roman Fabbricatore

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.

Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.

Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years or older.

The safety profile for tarlatamab was consistent with its known profile in patients with relapsed small cell lung cancer.

Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.

A disease-free survival and minimal residual disease event-free status was maintained for most patients with adjuvant osimertinib for EGFR-mutant NSCLC.

Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer.

A total of 32% of registered nurses and 29% of infusion nurses reported that educating patients regarding their diseases was challenging.

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

The ESMO Precision Oncology Working Group recommendations can serve as guidance to define standards for MTBs to integrate precision oncology into practice.

Patients with ALK-positive NSCLC not vulnerable to neurological adverse effects or prone to weight issues, might benefit from treatment with lorlatinib.

Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

The prespecified number of events required to undergo analyses of the secondary end points, including PFS, OS, and DOR, have not been met.

All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

No dose-limiting toxicities were seen with solnerstotug in patients with PD-L1–resistant tumors, and most adverse effects were grades 1/2 in severity.

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.

The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.

A radiation oncologist discussed challenges related to the radiation oncology space as well as ongoing developments in the field highlighted at ACRO.

Intravenous olvi-vec demonstrated a manageable safety and tolerability profile consistent with previous trials evaluating the investigational agent.

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.

Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

Increased incidence and mortality rates for cervical cancer among rural women in the US may result from barriers to access to care.